Gastroenterology and Liver

Advances in Hepatocellular Carcinoma Treatment

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and its treatment has seen significant advancements in recent years. Traditional therapies, such as surgical resection and liver transplantation, remain the cornerstone of curative treatment for early-stage HCC. However, these options are not suitable for all patients, particularly those with advanced disease or underlying liver dysfunction.

The advent of targeted therapies and immunotherapies has revolutionized the management of advanced HCC. Targeted agents, such as sorafenib and lenvatinib, inhibit specific molecular pathways involved in tumor growth and angiogenesis, offering a survival benefit for patients with advanced HCC. Immunotherapies, including immune checkpoint inhibitors like nivolumab and pembrolizumab, have shown promising results by enhancing the body's immune response against cancer cells, providing new hope for patients with previously limited treatment options.

Research is ongoing to identify biomarkers that can predict response to these therapies and to develop combination treatments that can overcome resistance mechanisms. Additionally, innovative approaches, such as gene therapy and personalized medicine, are being explored to improve outcomes for HCC patients. These advances underscore the importance of a multidisciplinary approach in the management of HCC, integrating surgical, medical, and interventional strategies to optimize patient care.